FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308434465> ?p ?o ?g. }

• W4308434465 endingPage "1531" @default.
• W4308434465 startingPage "1520" @default.
• W4308434465 abstract "UCART19 is an off-the-shelf genome-edited anti-CD19 chimeric antigen receptor (CAR)-T cell product, manufactured from unrelated healthy donor cells.UCART19 was administered to 25 adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) in the CALM trial. All patients underwent lymphodepletion with fludarabine and cyclophosphamide ± alemtuzumab and received one of three ascending doses of UCART19. Given the allogeneic nature of UCART19, we analyzed the impact of lymphodepletion, HLA disparities, and host immune system reconstitution on its kinetics, along with other factors known to affect autologous CAR-T cell clinical pharmacology.Responder patients (12/25) had higher UCART19 expansion (Cmax) and exposure (AUCTlast) than nonresponders (13/25), as measured by transgene levels in peripheral blood. The persistence of CAR+ T cells did not exceed 28 days in 10/25 patients and lasted beyond 42 days in 4/25. No significant correlation was found between UCART19 kinetics and administered cell dose, patient and product characteristics or HLA disparities. However, the number of prior lines of therapy and absence of alemtuzumab negatively impacted UCART19 expansion and persistence. Alemtuzumab exposure positively affected IL7 and UCART19 kinetics, while negatively correlating with host T lymphocyte AUC0-28.UCART19 expansion is a driver of response in adult patients with R/R B-ALL. These results shed light on the factors associated with UCART19 kinetics, which remain highly affected by the impact of alemtuzumab on IL7 and host-versus-graft rejection.First description of the clinical pharmacology of a genome-edited allogeneic anti-CD19 CAR-T cell product showing the crucial role of an alemtuzumab-based regimen in sustaining UCART19 expansion and persistence through increased IL7 availability and decreased host T lymphocyte population." @default.
• W4308434465 created "2022-11-11" @default.
• W4308434465 creator A5002813506 @default.
• W4308434465 creator A5007401286 @default.
• W4308434465 creator A5008084507 @default.
• W4308434465 creator A5011935547 @default.
• W4308434465 creator A5012456096 @default.
• W4308434465 creator A5021380291 @default.
• W4308434465 creator A5028379115 @default.
• W4308434465 creator A5029763484 @default.
• W4308434465 creator A5036148676 @default.
• W4308434465 creator A5040374787 @default.
• W4308434465 creator A5041455800 @default.
• W4308434465 creator A5058446224 @default.
• W4308434465 creator A5061277936 @default.
• W4308434465 creator A5071172286 @default.
• W4308434465 creator A5076973611 @default.
• W4308434465 creator A5078863187 @default.
• W4308434465 creator A5082541805 @default.
• W4308434465 date "2022-11-30" @default.
• W4308434465 modified "2023-10-03" @default.
• W4308434465 title "Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia" @default.
• W4308434465 cites W1556687169 @default.
• W4308434465 cites W1619537825 @default.
• W4308434465 cites W1839053269 @default.
• W4308434465 cites W1972819312 @default.
• W4308434465 cites W2022877662 @default.
• W4308434465 cites W2026252733 @default.
• W4308434465 cites W2030259772 @default.
• W4308434465 cites W2035800776 @default.
• W4308434465 cites W2049115432 @default.
• W4308434465 cites W2067650601 @default.
• W4308434465 cites W2118796952 @default.
• W4308434465 cites W2126769212 @default.
• W4308434465 cites W2129702476 @default.
• W4308434465 cites W2139761231 @default.
• W4308434465 cites W2265134611 @default.
• W4308434465 cites W2285239684 @default.
• W4308434465 cites W2342423058 @default.
• W4308434465 cites W2398243892 @default.
• W4308434465 cites W2509364267 @default.
• W4308434465 cites W2602369513 @default.
• W4308434465 cites W2606654718 @default.
• W4308434465 cites W2760653955 @default.
• W4308434465 cites W2761657464 @default.
• W4308434465 cites W2773804840 @default.
• W4308434465 cites W2787301955 @default.
• W4308434465 cites W2787621143 @default.
• W4308434465 cites W2788841996 @default.
• W4308434465 cites W2801641802 @default.
• W4308434465 cites W2807103182 @default.
• W4308434465 cites W2807819616 @default.
• W4308434465 cites W2883797118 @default.
• W4308434465 cites W2891902322 @default.
• W4308434465 cites W2910803005 @default.
• W4308434465 cites W2917127842 @default.
• W4308434465 cites W2940961021 @default.
• W4308434465 cites W2944669426 @default.
• W4308434465 cites W2948047060 @default.
• W4308434465 cites W2984295746 @default.
• W4308434465 cites W2998345757 @default.
• W4308434465 cites W3014583893 @default.
• W4308434465 cites W3082855561 @default.
• W4308434465 cites W3092023747 @default.
• W4308434465 cites W3094184602 @default.
• W4308434465 cites W3113171896 @default.
• W4308434465 cites W3116504222 @default.
• W4308434465 cites W3121519579 @default.
• W4308434465 cites W3169193862 @default.
• W4308434465 cites W4200626931 @default.
• W4308434465 cites W4304112200 @default.
• W4308434465 cites W4308434413 @default.
• W4308434465 doi "https://doi.org/10.1158/2767-9764.crc-22-0175" @default.
• W4308434465 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36970059" @default.
• W4308434465 hasPublicationYear "2022" @default.
• W4308434465 type Work @default.
• W4308434465 citedByCount "3" @default.
• W4308434465 countsByYear W43084344652022 @default.
• W4308434465 countsByYear W43084344652023 @default.
• W4308434465 crossrefType "journal-article" @default.
• W4308434465 hasAuthorship W4308434465A5002813506 @default.
• W4308434465 hasAuthorship W4308434465A5007401286 @default.
• W4308434465 hasAuthorship W4308434465A5008084507 @default.
• W4308434465 hasAuthorship W4308434465A5011935547 @default.
• W4308434465 hasAuthorship W4308434465A5012456096 @default.
• W4308434465 hasAuthorship W4308434465A5021380291 @default.
• W4308434465 hasAuthorship W4308434465A5028379115 @default.
• W4308434465 hasAuthorship W4308434465A5029763484 @default.
• W4308434465 hasAuthorship W4308434465A5036148676 @default.
• W4308434465 hasAuthorship W4308434465A5040374787 @default.
• W4308434465 hasAuthorship W4308434465A5041455800 @default.
• W4308434465 hasAuthorship W4308434465A5058446224 @default.
• W4308434465 hasAuthorship W4308434465A5061277936 @default.
• W4308434465 hasAuthorship W4308434465A5071172286 @default.
• W4308434465 hasAuthorship W4308434465A5076973611 @default.
• W4308434465 hasAuthorship W4308434465A5078863187 @default.
• W4308434465 hasAuthorship W4308434465A5082541805 @default.
• W4308434465 hasBestOaLocation W43084344651 @default.

• next